CordenPharma White Paper >>

Oligonucleotides: Promising Therapeutics With Significant Challenges

By Matthieu Giraud, PhD, Director, Global Peptides, Oligonucleotides, Lipids & Carbohydrates Platform
CordenPharma International

 


In recent years, interest in oligonucleotide therapeutics
has shown a resurgence, as new approaches, clinical
applications, advances in delivery, and a deeper biological
understanding of these compounds emerge. However,
expectations have been largely unfulfilled, as only three
oligonucleotide drugs have been approved by the FDA for
use in the United States as of August 2017. Get informed
about
W
hat's Driving the Interest in Oligonucleotides, as
well as
The Key Challenges of Oligo Drug Development,
Drug Delivery and Regulatory Guidelines.

 

 Tell us about yourself:

To Opt-out of future CordenPharma Emails Click Here

View CordenPharma's Privacy Policy Here